Compare Abbott Laboratories (ABT) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Dow Inc — how do they compare? Abbott Laboratories trades at $109.6 (market cap $187.95B), while Dow Inc trades at $31.2 (market cap $22.09B). The key difference: Abbott Laboratories is far larger — about 8.5× Dow Inc's market cap, and Dow Inc pays the higher dividend (4.58%). Which is the better fit depends on your goals.
| ABT | DOW | |
|---|---|---|
Market Cap | $187.95B | $22.09B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $41.87 |
52-Week Low | $82.57 | $20.65 |
Enterprise Value | $214.96B | $37.78B |
Dividend Yield | 2.32% | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
DOW trades at $29.34, down 3.17% today, with technical indicators showing bearish momentum. The company faces fundamental challenges with negative net income margin of -3.13% and declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings beats provide some optimism, but cash flow from operations has weakened significantly from $7.5B in 2022 to $1.0B in 2025. The stock trades near the lower end of analyst price targets with consensus at $35.11.
DOW presents a mixed investment case with valuation metrics showing potential undervaluation (P/S 0.51) offset by profitability concerns. The chemical sector faces cyclical pressures, but recent dividend payments and earnings beats suggest operational resilience. Key risks include continued revenue decline and high debt levels approaching 30% of assets. Analyst sentiment remains cautious with only 33% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
